Zexian Zeng

Peking University
Country flagChina

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (9)

Resistance to immune-mediated destruction is a fundamental hallmark of cancer. Although several mechanisms have been identified that facilitate immune evasion, the transcriptional programs that orchestrate this process remain poorly understood. In this study, through a genome-wide CRISPR activation screen in human cancer cells subjected to NK cell–mediated killing, we identified ZNF296, a transcription factor highly expressed in epithelial cancers, as a key driver of tumor resistance to both NK and cytotoxic T-cell–mediated immunity. In mouse models, inhibition of ZNF296 significantly enhanced both NK and T-cell–mediated antitumor immunity, leading to a marked reduction in metastasis and increased infiltration of immune cells into the tumor microenvironment. Mechanistically, ZNF296 induced strong transcriptional repression of IFN-stimulated genes and key immunostimulatory ligands critical for NK and T-cell–mediated cytotoxicity. At the molecular level, ZNF296 directly interacted with and recruited the NuRD chromatin remodeling and deacetylase complex to the promoters of its target genes to suppress expression. Notably, treatment with low-dose romidepsin, an FDA-approved inhibitor targeting histone deacetylase 1, a core component of the NuRD complex, effectively restored NK and T-cell–mediated killing in cancer cells with high ZNF296 expression. Collectively, these findings establish ZNF296 as a key regulator of immune evasion, driving resistance to both NK and T-cell–mediated antitumor immunity, and highlight its potential as a therapeutic target to overcome immune resistance in epithelial cancers. Significance: ZNF296 is a transcriptional regulator that enables cancer cells to evade immune surveillance, offering possibilities for developing treatments that enhance the ability of the immune system to eliminate cancer cells.

Year:

2026

Year:

2026

Resistance to immune-mediated destruction is a fundamental hallmark of cancer. Although several mechanisms have been identified that facilitate immune evasion, the transcriptional programs that orchestrate this process remain poorly understood. In this study, through a genome-wide CRISPR activation screen in human cancer cells subjected to NK cell–mediated killing, we identified ZNF296, a transcription factor highly expressed in epithelial cancers, as a key driver of tumor resistance to both NK and cytotoxic T-cell–mediated immunity. In mouse models, inhibition of ZNF296 significantly enhanced both NK and T-cell–mediated antitumor immunity, leading to a marked reduction in metastasis and increased infiltration of immune cells into the tumor microenvironment. Mechanistically, ZNF296 induced strong transcriptional repression of IFN-stimulated genes and key immunostimulatory ligands critical for NK and T-cell–mediated cytotoxicity. At the molecular level, ZNF296 directly interacted with and recruited the NuRD chromatin remodeling and deacetylase complex to the promoters of its target genes to suppress expression. Notably, treatment with low-dose romidepsin, an FDA-approved inhibitor targeting histone deacetylase 1, a core component of the NuRD complex, effectively restored NK and T-cell–mediated killing in cancer cells with high ZNF296 expression. Collectively, these findings establish ZNF296 as a key regulator of immune evasion, driving resistance to both NK and T-cell–mediated antitumor immunity, and highlight its potential as a therapeutic target to overcome immune resistance in epithelial cancers. Significance: ZNF296 is a transcriptional regulator that enables cancer cells to evade immune surveillance, offering possibilities for developing treatments that enhance the ability of the immune system to eliminate cancer cells.

Year:

2026

Spatial transcriptomics enables multiplex profiling of gene cellular expression and location within the tissue context. Although large volumes of spatial transcriptomics data have been generated, the lack of systematic curation and analysis limits biological discovery. We present Spatial transcriptOmics Analysis Resource (SOAR), a comprehensive spatial transcriptomics platform with 3461 uniformly processed samples across 13 species, 42 tissue types, and 19 different spatial transcriptomics technologies. Using SOAR, we found that CXCL16 / SPP1 macrophage polarity characterizes the coordination of immune cell polarity in the tumor microenvironment. SOAR’s integrative approach toward drug discovery revealed sirolimus and trichostatin A as potential anticancer agents targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin growth and proliferation pathway and identified Janus kinase/signal transducers and activators of transcription inhibitors for ulcerative colitis treatment. SOAR’s results demonstrate its broad application to data generated from diverse spatial technologies and pathological conditions. SOAR will support future benchmarking studies and method development, facilitating discoveries in molecular functions, disease mechanisms, and potential therapeutic targets.

Year:

2025

Tumor-associated macrophages (TAM) display remarkable functional heterogeneity, yet the molecular mechanisms driving their diverse phenotypes remain elusive. Using CRISPR screens in primary macrophages, we identified tumor-derived factors, including lactic acid, prostaglandin E2, and GM-CSF, as key modulators of TAM polarization. These factors interacted cooperatively and antagonistically to shape distinct TAM phenotypes that were highly conserved across human cancers. Mechanistically, lactic acid and PGE2 jointly induced angiogenic gene programs while suppressing GM-CSF–driven MHC-II expression at the chromatin level, creating mutually exclusive distributions of proangiogenic and MHC-II+ TAMs, which were differentially localized to specific spatial niches in the tumor microenvironment. Furthermore, we showed that shifting TAMs to an interferon-responsive phenotype, triggered by Adar inactivation, significantly promoted the infiltration of effector CD8+ T cells through specific receptor–ligand interactions. These findings uncover a conserved mechanism of TAM polarization and offer insights into therapeutic strategies for TAM reprogramming to potentiate cancer immunotherapy.

Year:

2025

Tumor-associated macrophages (TAM) display remarkable functional heterogeneity, yet the molecular mechanisms driving their diverse phenotypes remain elusive. Using CRISPR screens in primary macrophages, we identified tumor-derived factors, including lactic acid, prostaglandin E2, and GM-CSF, as key modulators of TAM polarization. These factors interacted cooperatively and antagonistically to shape distinct TAM phenotypes that were highly conserved across human cancers. Mechanistically, lactic acid and PGE2 jointly induced angiogenic gene programs while suppressing GM-CSF–driven MHC-II expression at the chromatin level, creating mutually exclusive distributions of proangiogenic and MHC-II + TAMs, which were differentially localized to specific spatial niches in the tumor microenvironment. Furthermore, we showed that shifting TAMs to an interferon-responsive phenotype, triggered by Adar inactivation, significantly promoted the infiltration of effector CD8 + T cells through specific receptor–ligand interactions. These findings uncover a conserved mechanism of TAM polarization and offer insights into therapeutic strategies for TAM reprogramming to potentiate cancer immunotherapy.

Year:

2025

Recent advancements in spatial transcriptomics technologies have significantly enhanced resolution and throughput, underscoring an urgent need for systematic benchmarking. Here, we generate serial tissue sections from colon adenocarcinoma, hepatocellular carcinoma, and ovarian cancer samples for systematic evaluation. Using these uniformly processed samples, we generate spatial transcriptomics data across four high-throughput platforms with subcellular resolution: Stereo-seq v1.3, Visium HD FFPE, CosMx 6K, and Xenium 5K. To establish ground truth datasets, we profile proteins on tissue sections adjacent to all platforms using CODEX and perform single-cell RNA sequencing on the same samples. Leveraging manual nuclear segmentation and detailed annotations, we systematically assess each platform’s performance across capture sensitivity, specificity, diffusion control, cell segmentation, cell annotation, spatial clustering, and concordance with adjacent CODEX. The uniformly generated and processed multi-omics dataset could advance computational method development and biological discoveries. The dataset is accessible via SPATCH, a user-friendly web server for visualization and download.

Year:

2025

Effective immunotherapy relies on the presentation of tumor-derived neoantigens on the major histocompatibility complex class I (MHC-I) to activate CD8+ T cells. Deficiencies in this process are a key mechanism of immune evasion and resistance to checkpoint blockade. In this study, using an in vivo CRISPR-Cas9 screen, we unexpectedly found that inactivation of calreticulin (CALR), and other selected components of the peptide-loading complex (PLC), induced robust CD8+ T cell–mediated immune responses. We show that this effect is dependent on the expression of classical MHC-I on tumor cells. Mechanistically, loss of CALR reshaped the MHC-I peptide repertoire, favoring the presentation of low-affinity peptides in murine and human cell lines. Genetic or pharmacological inhibition of PDIA3, another PLC component, similarly induced antitumor effects. These findings reveal a previously unrecognized role of CALR and the PLC in regulating antitumor immunity and suggest that targeting this pathway could be a promising strategy to overcome immune resistance and improve the efficacy of cancer immunotherapies.

Year:

2025

Year:

2023

Collaborators (6)

Yuan Luo

Chief AI Officer and Associate Professor

Northwestern University

UNITED STATES
View details

Hanqiu Zheng

Principal Investigator

Tsinghua University

CHINA
View details

Chengsheng Mao

Research Assistant Professor

Northwestern University

UNITED STATES
View details

Parambir S Dulai

Northwestern University

UNITED STATES
View details

Arthur Oubrie

Chief Scientific Officer

-

NETHERLANDS
View details

Yawei Li

Research Assistant Professor

Northwestern University Feinberg School of Medicine

UNITED STATES
View details